Lisa-Jane K Graham
Overview
Explore the profile of Lisa-Jane K Graham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fettke H, Dai C, Kwan E, Zheng T, Du P, Ng N, et al.
EBioMedicine
. 2023 Aug;
95:104738.
PMID: 37549632
Background: Genomic alterations in DNA damage response (DDR) genes are common in metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment response is vital for...
2.
Kwan E, Dai C, Fettke H, Hauser C, Docanto M, Bukczynska P, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250422
Methods: A next-generation sequencing-based cfDNA assay was used to profile 231 patients with mCRPC from two independent cohorts (Australian, n = 78; United States, n = 153). PTEN-PI3K-AKT pathway genomic...
3.
Kwan E, Fettke H, Crumbaker M, Docanto M, To S, Bukczynska P, et al.
Transl Androl Urol
. 2021 May;
10(4):1688-1699.
PMID: 33968657
Background: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value...
4.
Fettke H, Kwan E, Docanto M, Bukczynska P, Ng N, Graham L, et al.
Eur Urol
. 2020 Jun;
78(2):173-180.
PMID: 32487321
Background: The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profiling AR aberrations in both circulating DNA and RNA may identify key predictive and/or prognostic...
5.
Kwan E, Fettke H, Docanto M, To S, Bukczynska P, Mant A, et al.
Eur Urol Focus
. 2019 May;
7(1):63-70.
PMID: 31103601
Background: The treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly in recent years. Identifying predictive and/or prognostic biomarkers in the context of this rapidly expanding therapeutic armamentarium...
6.
To S, Kwan E, Fettke H, Mant A, Docanto M, Martelotto L, et al.
Eur Urol
. 2018 Feb;
73(6):818-821.
PMID: 29398263
Patient Summary: Detection of androgen receptor splice variants (AR-Vs) in circulating tumour cells of advanced prostate cancer patients has been linked to resistance to abiraterone and enzalutamide. We designed a...
7.
Brooke D, van Dam E, Watts C, Khoury A, Dziadek M, Brooks H, et al.
Bioorg Med Chem
. 2014 Jan;
22(3):1029-39.
PMID: 24398380
High-throughput screening of a small-molecule library identified a 5-triazolo-2-arylpyridazinone as a novel inhibitor of the important glycolytic enzyme 6-phosphofructo-2-kinase/2,6-bisphosphatase 3 (PFKFB3). Such inhibitors are of interest due to PFKFB3's control...